Zhejiang Jianfeng Group Co Ltd

Jianfeng Group announced that its subsidiary Anhui Jianfeng Beika Pharmaceutical has received a CEP certificate for the methyldopa active pharmaceutical ingredient issued by the European Directorate for the Quality of Medicines and HealthCare, effective from September 22, 2026. Methyldopa was developed by Merck Sharp and Dohme and approved for marketing in the United States in 1962. It is the world's first-generation centrally acting antihypertensive drug and a classic first-choice medication for gestational hypertension. Jianfeng Beika submitted its CEP certificate application in July 2025 and it was accepted. The product had previously received approval for a domestic chemical API marketing application. The announcement stated that obtaining the CEP certificate demonstrates recognition of the quality of this API in the European regulated market, signifying that the product is qualified to enter the European Union and other markets that recognize CEP certificates in API form, bringing a positive impact to the company's further expansion into international markets.

Jianfeng Group announced that its subsidiary Jianfeng Beika has received the Chemical API Marketing Application Approval Notice for methyldopa from the National Medical Products Administration, valid until August 24, 2031. Methyldopa was developed by Merck Sharp and Dohme and approved for marketing in the United States in 1962. It is the world's first-generation centrally acting antihypertensive drug and a classic first-choice medication for hypertension during pregnancy. Jianfeng Beika submitted its technical review application in March 2025, with cumulative research and development investment of approximately 3.36 million yuan. The company stated that this approval indicates the API meets relevant national technical review standards and can be sold in the domestic market, helping to expand the subsidiary's business areas.

Jianfeng Group announced that its wholly-owned subsidiary Jianfeng Pharmaceutical has received the drug registration certificate for Compound Tropicamide Eye Drops approved and issued by the National Medical Products Administration. The product specification is 5 ml containing 25 mg of tropicamide and 25 mg of phenylephrine hydrochloride, classified as a Category 4 chemical drug, and is mainly used for mydriasis and cycloplegia for diagnostic and therapeutic purposes. The announcement shows that the drug has been included in the National Reimbursement Drug List Category B and the National Essential Drug List.

This evening, nearly 100 companies listed on the Shanghai Stock Exchange released a flurry of positive signals, spanning share buybacks and stake increases, improving business performance, proposed selections in centralized drug procurement, and interim dividend returns. On the buyback and stake increase front, two new buyback plans were added by Bethel Automotive Safety Systems and Shandong Hi-Speed, with a combined proposed buyback cap of 400 million yuan. Soochow Securities disclosed a controlling shareholder's stake increase plan, with a proposed increase amount not exceeding 200 million yuan, while another 76 companies simultaneously disclosed progress updates on buybacks and stake increases. At the operational level, results of the 12th round of national centralized drug procurement were gradually announced, with multiple Shanghai-listed pharmaceutical companies including Harbin Pharmaceutical Group, Zhejiang Huahai Pharmaceutical, China Resources Double-Crane Pharmaceutical, North China Pharmaceutical, Jiangsu Lianhuan Pharmaceutical, Aurisco Pharmaceutical, and Jianfeng Group declaring that their products have been proposed for selection. In terms of investor returns, four companies—WuXi AppTec, Zhejiang Jiuzhou Pharmaceutical, Kingfa Sci. & Tech., and Jasan Group—unveiled interim dividend plans on the same day. Among them, WuXi AppTec plans to distribute a cash dividend of 5.1 yuan per 10 shares, with the total interim dividend expected to exceed 1.5 billion yuan. Additionally, the controlling shareholder of Lujiazui voluntarily committed not to transfer or reduce its holdings in any way within the next 12 months, coinciding with the unlocking of restricted shares from the company's private placement.

Jianfeng Group announced that its wholly-owned subsidiary Jianfeng Pharmaceutical has received the Drug Registration Certificate for Tedizolid Phosphate for Injection issued by the National Medical Products Administration. The drug specification is 200 mg, approved as a Category 4 chemical drug, and deemed to have passed the consistency evaluation. It is indicated for the treatment of acute bacterial skin and skin structure infections caused by susceptible isolates of Gram-positive bacteria.